Drug Trial Radar · NCT00717470
A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection
Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,252
Actual
Start
May 14, 2008
Primary completion
Mar 2, 2010
Study completion Mar 2, 2010
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jul 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare how well the new formulation of Tacrolimus® used once daily, in combination with other drugs helps prevent the rejection of a new kidney after transplantation compared to the twice daily dose of Tacrolimus
Conditions
- Kidney Transplantation
Interventions
Prograf®Drug
oral
Advagraf®Drug
oral
Mycophenolate MofetilDrug
oral
SimulectDrug
oral
methylprednisolone / prednisoneDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy failure rateTime frame: 24 weeks
Locations
110 sites in 22 countries. Site status is shown where the registry gives one.
Site not named
Buenos Aires, Argentina
Site not named
Córdoba, Argentina
Site not named
Innsbruck, Austria
Site not named
Linz, Austria
Site not named
Vienna, Austria
Site not named
Brussels, Belgium
Site not named
Brussels, Belgium
Site not named
Ghent, Belgium
Site not named
Leuven, Belgium
Site not named
Brno, Czechia
Site not named
Hradec Kravlove, Czechia
Site not named
Ostrava, Czechia
Site not named
Prague, Czechia
Site not named
Angers, France
Site not named
Bordeaux, France
Site not named
Brest, France
Site not named
Créteil, France
Site not named
La Tronche, France
Site not named
Le Kremlin-Bicêtre, France
Site not named
Limoges, France
Site not named
Lyon, France
Site not named
Nantes, France
Site not named
Nice, France
Site not named
Paris, France
Site not named
Paris, France
Site not named
Paris, France
Site not named
Rennes, France
Site not named
Saint-Etienne, France
Site not named
Strasbourg, France
Site not named
Suresnes, France
Site not named
Toulouse, France
Site not named
Tours, France
Site not named
Vandœuvre-lès-Nancy, France
Site not named
Aachen, Germany
Site not named
Berlin, Germany
Site not named
Essen, Germany
Site not named
Frankfurt, Germany
Site not named
Freiburg I. Br, Germany
Site not named
Halle, Germany
Site not named
Hamburg, Germany
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.